Streptogramin-based gene regulation systems for mammalian cells

Here we describe repressible (PipOFF) as well as inducible (PipON) systems for regulated gene expression in mammalian cells, based on the repressor Pip (pristinamycin-induced protein), which is encoded by the streptogramin resistance operon of Streptomyces coelicolor. Expression of genes placed under control of these systems was responsive to clinically approved antibiotics belonging to the streptogramin group (pristinamycin, virginiamycin, and Synercid). The versatility of these systems was demonstrated by streptogramin-regulated expression of mouse erythropoietin (EPO), human placental secreted alkaline phosphatase (SEAP), or green fluorescent protein (GFP) in diverse cell lines (BHK, CHO, HeLa, and mouse myoblasts). Analysis of isogenic constructs in CHO cells demonstrated the PipOFF system gave lower background and higher induction ratios than the widely used tetracycline-repressible (TetOFF) expression systems. The streptogramin-based expression technology was functionally compatible with the TetOFF system, thus enabling the selective use of different antibiotics to independently control two different gene activities in the same cell.

[1]  V. Corces,et al.  Identification of sequences involved in the transcriptional control of a Drosophila heat-shock gene. , 1984, The Journal of biological chemistry.

[2]  S. McKnight,et al.  Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression. , 1988, Genes & development.

[3]  B. Cullen,et al.  Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. , 1988, Gene.

[4]  M. Labow,et al.  A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature and isopropyl beta-D-thiogalactopyranoside. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Busslinger,et al.  A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Y Wang,et al.  A regulatory system for use in gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. Hillen,et al.  Mechanisms underlying expression of Tn10 encoded tetracycline resistance. , 1994, Annual review of microbiology.

[9]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[10]  C. Thompson,et al.  Stress‐activated expression of a Streptomyces pristinaespiralis multidrug resistance gene (ptr) in various Streptomyces spp. and Escherichia coli , 1995, Molecular microbiology.

[11]  C. Thompson,et al.  Molecular characterization and transcriptional analysis of a multidrug resistance gene cloned from the pristinamycin‐producing organism, Streptomyces pristinaespiralis , 1995, Molecular microbiology.

[12]  C. Thompson,et al.  Unusual regulatory mechanism for a Streptomyces multidrug resistance gene, ptr, involving three homologous protein‐binding sites overlapping the promoter region , 1995, Molecular microbiology.

[13]  R. Evans,et al.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Shannon R. Magari,et al.  A humanized system for pharmacologic control of gene expression , 1996, Nature Medicine.

[15]  D. Bohl,et al.  Modulation of erythropoietin delivery from engineered muscles in mice. , 1997, Human gene therapy.

[16]  M. Hagmann,et al.  Silencing of RNA Polymerases II and III-Dependent Transcription by the KRAB Protein Domain of KOX1, a Krüppel-Type Zinc Finger Factor , 1997, Biological chemistry.

[17]  D. Bouanchaud,et al.  A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas. , 1997, The Journal of antimicrobial chemotherapy.

[18]  F. Baquero.  Gram-positive resistance: challenge for the development of new antibiotics. , 1997, The Journal of antimicrobial chemotherapy.

[19]  J E Bailey,et al.  Autoregulated Multicistronic Expression Vectors Provide One‐Step Cloning of Regulated Product Gene Expression in Mammalian Cells , 1997, Biotechnology progress.

[20]  G. Montay,et al.  The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. , 1997, The Journal of antimicrobial chemotherapy.

[21]  M. Fussenegger,et al.  A novel cytostatic process enhances the productivity of Chinese hamster ovary cells. , 1997, Biotechnology and bioengineering.

[22]  F. Gage,et al.  High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Blau,et al.  Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16 , 1998, Nature Genetics.

[24]  Martin Fussenegger,et al.  Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells , 1998, Nature Biotechnology.

[25]  M. Fussenegger,et al.  pTRIDENT, a novel vector family for tricistronic gene expression in mammalian cells. , 1998, Biotechnology and bioengineering.

[26]  P Aebischer,et al.  Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts , 1998, Gene Therapy.

[27]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[28]  N. Déglon,et al.  Improvement of mouse β-thalassemia upon erythropoietin delivery by encapsulated myoblasts , 1999, Gene Therapy.

[29]  D. Bohl,et al.  Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells. , 1999, Human gene therapy.

[30]  Bessis,et al.  Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL‐4 or IL‐13 ameliorates murine collagen‐induced arthritis (CIA) , 1999, Clinical and experimental immunology.

[31]  M. Gossen,et al.  Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.